生物技术公司Celularity Inc.（纳斯达克：CELU）近日重申与NEXGEL, INC.（纳斯达克：NXGL）达成的战略商业化合作。该合作将依托双方现有商业化产品体系，共同构建生物材料领域的产品矩阵，同时积极开拓通过510(K)监管通道的新产品机会。
此次合作将整合Celularity在细胞疗法领域的创新技术与Nexgel的水凝胶材料平台优势，旨在加速创伤修复、组织再生等医疗场景的生物材料解决方案落地。双方计划通过资源互补，推动已上市产品的市场扩张，并针对510(K)豁免途径开发新一代医疗产品。
合作双方表示，这一战略伙伴关系将强化其在生物材料市场的竞争力，为医疗行业提供更全面的产品组合。通过协同创新与商业化运营，双方期待开拓新的增长路径，提升在再生医学领域的影响力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.